In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Maureen Kenny

Executive Editor

London, UK
Maureen's expertise in bringing exclusive, business-critical content to the expanded Pink Sheet audience builds upon her many years' experience as an editor and reporter. Most recently, Maureen headed Scrip Regulatory Affairs, an indispensable publication for both pharmaceutical and medtech regulatory affairs professionals worldwide. She managed the publication's move from print to digital. Previous leadership roles also include being editor of Clinica Medtech Intelligence and acting editor of Scrip Intelligence. She chaired the DIA EuroMeeting plenary session in Paris in April 2015 and spent two years in New York covering the pharmaceutical industry in the US, Canada and, being a fluent Spanish speaker, Latin America. Maureen is based in London.
Advertisement
Set Alert for Articles By Maureen Kenny

Latest From Maureen Kenny

EU Accelerated Assessment Tracker

Roche has secured accelerated assessment at the European Medicines Agency for its new immunosuppressant, satralizumab. The outcomes of five other fast-track requests that companies have made for their planned marketing authorization applications are still unknown.

Europe European Performance Tracker

New Filings At The EMA

New medicines under evaluation at the European Medicines Agency.

Europe Drug Review

Roche Takes Orphan Satralizumab To EMA

There are six new entries on the latest list of products under review at the European Medicines Agency – products with orphan status from Roche and Novo Nordisk and four generic or biosimilars.

Europe Drug Review

EU Accelerated Assessment Tracker

The outcomes of six requests for accelerated assessment that companies have made for their planned marketing authorization applications in the EU are still unknown.

Europe Drug Review

Roche’s Polivy Reverts To Standard Review In EU

Just two products are being assessed under the EMA's fast-track mechanism now that the marketing application for Roche's Polivy has reverted to standard review.

Europe BioPharmaceutical

EMA Monitors CDK 4/6 Inhibitors; US Issues Serious Side Effect Warning

Cases of "rare but serious" lung inflammation have been seen in breast cancer patients undergoing treatment with CDK 4/6 inhibitors. The US regulator has taken action and the European Medicines Agency is monitoring the situation in Europe.
Europe North America
See All
Advertisement
UsernamePublicRestriction

Register